Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Par Gets Approval for Depression Drug | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Par Gets Approval for Depression Drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Par Pharmaceutical Co.’s wholly-owned subsidiary, Kali Laboratories, Inc., received final approval from the FDA for its aNDA for tranylcypromine sulfate tablets, 10 mg. Tranylcypromine is the generic version of GlaxoSmithKline’s Parnate and is used for the treatment of depression. Annual U.S. sales of Parnate exceed $6 million. Par will begin shipping the product immediately.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters